A conference call will be held today, Wednesday, October 22, 5:00 p.m. E.D.T. DUSA Pharmaceuticals, Inc.® (NASDAQ GM: DUSA) announced today results from its Phase IIB clinical trial to compare the ...
Aminolevulinic acid HCl 20%; topical soln; contains alcohol. Following the application of Levulan Kerastick topical solution, photosensitization occurs through the metabolic conversion of ...
LEVULAN KERASTICK offers patients and health care practitioners a treatment option with a well-established safety and efficacy profile that can prevent the progression of actinic keratoses into skin ...
SAN FRANCISCO (MarketWatch) -- Dusa Pharmaceuticals Inc. shares leapt 35% to $3.75 in Thursday morning trade. The Wilmington, Mass.-based company announced that the Food and Drug Administration has ...
June 1, 2007 — The US Food and Drug Administration (FDA) has granted orphan drug designation for aminolevulinic acid HCl in combination with photodynamic therapy for the treatment of esophageal ...
LEVULAN KERASTICK for topical solution, 20%, plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is used to treat minimally to moderately thick actinic keratoses ...
Says FDA did not grant orphan status to Levulan therapy Levulan developed for prevention of skin cancer Co plans to close its SOTR clinical program Shares plunge 18 pct Aug 6 (Reuters) - DUSA ...
Sun Pharmaceutical Industries has announced it will acquire DUSA Pharmaceuticals for approximately $230 million in cash, according to a news release (pdf). DUSA is a Wilmington, Mass-based dermatology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback